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CHOLERA IN WEST AFRICA
Since El Tor cholera, Ogawa serotype, was introduced into Guinea 
in August of 1970, cholera disease has been reported from 13 
West African countries. Cholera had not been recognized in West 
Africa since 1894, nor had its known spread been so extensive.1 
The countries which have officially reported cholera are Guinea,
Sierra Leone, Liberia, Mali, Ivory Coast, Ghana, Upper Volta, Togo, 
Dahomey, Niger, Nigeria, Cameroon and Chad. The progress of this 
disease as it moved from west to east can be seen in Figure I.
(Data not yet available from Chad.) Its spread followed basically 
one of two routes, the coast bordering the Gulf of Guinea or the 
Niger River. Thus, water (although in a different sense than the 
common source water-borne outbreak described by Snow2 at the 
Broadstreet Pump in London in 1854) played a major role in the 
dissemination of cholera. In both of these areas, water serves 
as the major transportation and communication link within and 
between countries. In the coastal area, the fishermen and 
traders who ply the coast without respect to international 
borders gradually brought the disease eastward approximately 1,750 
miles over a five month period. Along the Niger River, the mode 
of spread by fishermen and travelers was similar, the rate of 
spread faster and the effect the same. Once cholera was introduced 
into a given region or village, multiple factors such as the availa­
bility of a safe water supply, the cooking practices, and the level 
of personal hygiene and community sanitation influenced the effect 
of the importation.
II. ATTACK RATES
The total number of people infected with the disease will never 
be accurately known. Present official totals from 12 countries 
indicate approximately 24,075 clinical cases with 3,445 deaths.
Based on the report of Bart, et al,3 who found 36 sub-clinical 
infections for every clinical case of El Tor cholera, it can be 
estimated that there have been at least 870,000 cholera infections 
in West Africa since August 1970. Reported cholera cases, deaths, 
attack rates, and case fatality ratios are presented by country 
in Table I. Country-wide attack rates are difficult to interpret 
because a given area within a country may have a very high attack 
rate although the country itself would appear to have been rela­
tively unaffected by the disease. For example, one country with 
an attack rate of less than 0.5 per 1000 persons had an area where the
^Politzer, R., Cholera, 1959, WHO Tech. Series, No. 43, Geneva, 
Switzerland.
2Snow on Cholera, Commonwealth Fund, New York, 1936.
3Bart, K.J., et al, J. Inf. Dis. 121:S17, 1970.
I. OVERVIEW
cholera mortality rate was 10.5/1000. The attack rate for the 
coastal region'* is 1.46 reported cases per 1,000 persons. In 
the subsaharan savannah belt5 the attack rate is approximately
0.64 reported cases per 1,000 persons.
MORTALITY AND TREATMENT
The mean case-fatality ratio shown in Table I is 14 deaths per 
100 cases with a range of 3 to 45. Countries which were well 
prepared for the disease through education of health personnel 
in cholera treatment, preparation and distribution of treatment 
supplies, and good laboratory supported surveillance, were able 
to keep their case-fatality ratio to a minimum of about 5 per 
100. They have demonstrated that disease management in Africa 
can result in very low case-fatality ratios similar to those 
reported from the SEATO-Pakistan Cholera Research Laboratory 
in Dacca and the Johns Hopkins University Center for Medical 
Research and Training, School of Tropical Medicine, Calcutta, 
India,6 and other treatment centers.
SPECIAL EPIDEMIOLOGIC SITUATIONS
A. Rivers
Although the coastal area and the Niger River have been the
main avenues of disease spread, within inland areas smaller
fresh water rivers used as the primary souvce for water have 
carried the disease downstream from infected villages to 
previously uninfected ones. Along brackish coastal rivers 
not used for drinking water, the disease has spread upstream 
via contaminated food items or infected people.
B. Markets
Markets, also, are an excellent source of transmission through 
contamination of food being handled by infected people in 
local markets. A good example is fish, particularly dried 
fish which become contaminated after the drying process is 
completed at the time of sale by the local vendors. The 
freshening of market vegetables with water, a common practice 
in West Africa, led to an outbreak in Israel when contaminated 
water was used.7 The market in Mopti was the first major source 
of dissemination of cholera along the Niger River in Mali.
^Southern Parts of Ivory Coast, Ghana, Togo, Dahomey, Cameroon. 
5Portions of Mali, Upper Volta, Niger (See Table I for specific 
areas included).
6Carpenter, C.C.J., et al, 1966, Bull. Johns Hopkins Hosp. , 118: 
174; Gordon, R., et al, 1964, PakMed.J. 8:10; Wallace, C.K., et 
al, 1968, Bull. WHO 39, 239.
7Langmuir, A.D., Epi-AID Memo 71-36-2.
C. Cholera Illness and Death
Because of their importance in the West African situation, 
the role played by the sick and dead person in the trans­
mission of cholera should be noted. People who become ill 
often return to their home village bringing with them their 
disease. Such people have been documented to be the source 
of introduction of cholera into previously uninfected 
villages. In some cultures, if the person should die, the 
funeral preparations are conducive to disease transmission.
The body may be washed and handled quite extensively by the 
mourning immediate family members. Although burial is 
prompt, the ceremony which accompanies it attracts many 
relatives and friends from various distances. In some 
societies ceremonies will last a number of days and be 
repeated several times during the months after death. The 
clothes or bedding of the deceased may be utilized during the 
ceremony, and great amounts of food, often uncooked, are 
prepared and shared by all people. There are frequent chances 
for common source food- and water-borne dissemination of the 
disease under such conditions.
VACCINATION
The SEATO-Pakistan Laboratory has calculated for Pakistan that it 
is cheaper and more productive to provide diarrhea treatment cen­
ters than to carry out vaccination programs.® Some countries in 
West Africa have mounted inexpensive vaccination programs by­
utilizing smallpox-measles teams and have shown that in particular 
areas vaccination may be one of the appropriate methods of combat­
ting the disease. Each country or region should evaluate its own 
particular situation by attempting to predict the amount of disease 
and anticipating the relative cost of prevention and the relative 
cost of treatment. In areas which have the characteristics of 
being readily accessible, expecting a large amount of disease, and 
for which personnel or other treatment facilities are marginal or 
unavailable, vaccination may be a very viable choice. In other 
areas extensive treatment capability, safe water and food sources, 
geographic inaccessibility, and the importance of other vaccina­
tion campaigns may make vaccination inappropriate and the role of 
diarrhea treatment centers more important. Experience has shown 
that such centers established in West Africa can achieve the 
success which has previously been demonstrated in Pakistan and 
India and that effective adequate treatment is preferred over 
vaccination because of lower mortality rates.
8Sommer, A., Personal Communication.
VI. FUTURE ~ PREDICTIONS AND PLANNING 4
The future expectations and plans for cholera have a direct 
relationship to the future planning of health activities in 
West Africa. There has been disruption of planned maintenance 
and other smallpox-measles activities in many countries in 
response to the threat and actuality of cholera disease.
Many countries are now witnessing large increases in the 
number of measles cases. This might have been averted by 
appropriate mass vaccination against measles in lieu of the 
cholera activities.
The persistence of cholera disease in certain areas; for 
example, Central, Accra and Eastern Regions of Ghana for four 
months with some evidence of reinfection of certain persons 
and localities, raises the question of cholera becoming endemic 
with possible epidemic spread from these foci at various times 
under certain conditions. Disturbingly, the hardiness of the 
El Tor biotype and the large number of subclinical infections 
caused by the organism not only increase the chance of spread of 
disease, but have allowed this biotype to compete successfully 
with other bacteria in the environment. Countries such as the 
Philippines, Thailand'and Indonesia which had not been affected 
with El Tor cholera prior to the Seventh Pandemic became affected 
from 1961 to 1963 and they are still reporting disease. Thus,
West African countries should expect to have disease for a number 
of years, perhaps even a decade.
Cholera is known to reach epidemic proportions in Southeast 
Asia at various times of the year, in either the wet or dry 
season, depending on the locality and the people involved. The 
major effect may not be the environmental results of the weather, 
but the way weather affects the activities of people. As the 
rains begin in West Africa in May and June, communication between 
people will decrease as the travel conditions deteriorate, and 
in those areas with a predominant agricultural sector people will 
move to widely scattered farms. This will reduce the mixing of 
people and will decrease the possibility of disease transmission. 
For these reasons, we anticipate that cholera will continue to 
decrease over the next few months. Next fall, with an increase 
in travel, a regathering of farmers in their villages, and the 
waning of naturally acquired and vaccination immunity, cholera 
will again be a potential threat.
Thus, the need for surveillance is of paramount importance.
Because of the explosive nature of the disease, the origin and 
magnitude of any new foci which develop must be identified quickly.
*
ll
Efforts should be made to improve laboratory competence in this 
direction through adequate training and distribution of transport 
media. Medical personnel not trained cr experienced in treatment 
of cholera should receive instruction. Contingency plans should 
be made for establishment of treatment centers and/or vaccination 
programs, as appropriate, to avoid disruption of on-going programs. 
The possibility of adding cholera vaccine as an additional antigen 
to planned programs should be considered. Health education 
concerning the route of transmission of the disease should continue. 
Continued pressure must be maintained for the provision of safe 
water for all people. Areas of critically high population density, 
including all of the large cities, deserve special consideration 
and should be observed closely. It is these areas in which disease 
will be able to continue at a low level of transmission and from 
which future epidemics may develop.
V
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Reported Cholera Disease in West Africa
Country
Month of 
Peak N o . 
of Cases
Pop. at 
Highest Risk 
(Millions)
No. of 
Cases
Attack
Rate/
1.000
No. of 
Deaths
Case
Fatality
Ratio
Guinea Aug 3.91 2,000a 0.51 60 3
Sierra Leone Dec 2.51 340fa 0.14 47 14
Liberia Nov l.l1 201c 0.19 45 22
Ivory Coast Nov-Dee 1.52 l,500d 1.00 120 8
Mali Nov-Dee 3.9 3 3,491e 0.89 1,335 38
Ghana Jan-Feb 7.0“ 8,234¿ 1.17 417 5
(Southern Ghana 4.85 8,143^ 1.70 412 5)
Niger Jan 3.56 1,9133 0.55 336 18
Upper Volta Jan-Feb 1.17 7 222*1 0.19 102 45
Togo Dec-Jan 0.468 437* 0.95 25 6
Dahomey Jan 1.189 1,685-/ 1.43 251 16
Nigeria Jan-Apr NA 3,709fe NA 647 17
Cameroon Feb-Mar . 361 0 34 3l 0.95 60 17
TOTAL* 26.5 20,366 0.77 2,798 14
1 Total population used as demonimator because whole country infected or geographic 
extent of disease unclear
Southeast Ivory Coast only
Excluding Keyes Region
^Excluding Upper and Northern Regions
^Excluding Upper, Northern, Brong-Ahafo and Ashanti Regions
^Excluding Agadez and Diffa Regions
7Dori, Ouahigouya and Dedougou Sectors only
8Anecho, Vogan, Lome and Tabligbo Circumscriptions only
9South, Southeast and Southwest Departments only 
1°Wouri Department only
NA - Not Available
aReported for August 1970(WER 45,377, 4Sep70)
^Reported to March 20, 1971
^Reported to February 1, 1971
“Reported to March 1, 1971
^Reported to April 17, 1971
*Excluding Nigeria
Reported to mid-March 1971 
¿Reported to April 16, 1971 
^Reported to April 5, 1971 
^Reported to April 24, 1971 
./Reported to March 13, 1971 
^Reported to April 3, 1971 
"‘-Reported to March 20, 1971
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PRELIMINARY REPORT OF COMPARISON OF THE INTRADERMAL AND 
SUBCUTANEOUS ROUTES OF CHOLERA VACCINE ADMINISTRATION
I. INTRODUCTION
The introduction of El Tor cholera, Ogawa serotype, into 
Guinea in August 1970, and the subsequent spread of the 
disease through 13 other West African countries, (Section 
A, Figure 1), with a total population of approximately 100 
million people has produced the widest involvement of 
cholera in West Africa ever recorded. This relentless 
spread of disease put tremendous strain on the therapeutic 
and preventive health systems of the area. Because of the 
history of the Service Nationale des Grandes Endémies in 
Francophone West Africa, the Medical Field Units in Anglo­
phone West Africa, the more recent Smallpox/Measles Program, 
all of which have relied heavily on immunizations as a way 
of preventing disease, the governments and people of West 
Africa looked to mass immunization to prevent cholera disease 
and its spread.
>
The USPHS Advisory Committee on Vaccinations recommends an 
adult cholera immunization schedule of a primary dose of 0.5cc 
subcutaneously or intramuscularly followed four weeks later by 
a l.Occ dose subcutaneously or intramuscularly. The latest 
World Health Organization recommendation suggests separating 
the vaccinations by 7 to 28 days.1 If only one dose can be 
given, they recommend l.Occ S.C.
Because of the immediate and widespread desire for vaccination 
in West Africa, a shortage of vaccine developed. Governments 
without enough vaccine to administer the standard recommended 
dose to the population at risk followed the suggestions of 
the Cholera Service of the Institut Pasteur, Paris, and certain 
WHO personnel who recommended one intradermal dose of 0.2cc of 
cholera vaccine. These recommendations were based on the work 
of Panja2 and Singer3 who showed a rise in cholera agglutinating 
antibodies following the intradermal administration of 0.1 and
0.2 cc of cholera vaccine in a small group of people. Noble1* 
showed a rise in cholera agglutinating antibodies following 
administration of intradermal vaccine which was comparable to 
the rise seen following subcutaneous vaccination. However, only 
18 people were chosen for vaccination of whom only ten had no 
previous inoculation or exposure to cholera. There has been no 
field trial published which evaluates the protective effect of 
the intradermal administration of cholera vaccine.
Neeley, J.C., (1970) Public Health Papers, No. 40:87.
2Panja, G., and Das, N.W. (1947) Ind. Jour. Med. Res. 35:3. 
3Singer, E., et al, (1948) J. Immunol. 60:101.
“Noble, J.E. (1964) J. Hyg. Camb., 62:11.
Vaccine field trials have demonstrated the efficacy of subcu­
taneously administered cholera vaccine, although the protection 
is incomplete, 46-80%, and short lived (3-6 months)!?»6 »7»8 
Mosley, et al,9 have shown the predictive value of the vibrio- 
cidal antibody titer in evaluation of cholera vaccine and have 
demonstrated an inverse relationship between the cholera case 
rate and the vibriocidal titer. Specifically, there is 44% 
reduction in case rate for every doubling of vibriocidal titer.
In an effort to ascertain the relative effectiveness of the 
two different modes of cholera vaccine administration, a trial 
was carried out to compare the vibriocidal antibody response to 
the intradermal and subcutaneous routes of cholera vaccine 
administration.
II. MATERIALS AND METHODS
A. Vaccine
Freeze-dried cholera vaccine prepared after formalin 
inactivation of monovalent Ogawa and Inaba cultures was 
used. It was manufactured by Merck, Sharpe & Dohme, and 
was made available by Division of Biological Standards, 
National Institutes of Health, Bethesda, Maryland, under 
DBS-IND 313. The vaccine was reconstituted using sterile 
isotonic 0.02 molar phosphate buffered saline, pH 7.2 
containing 0.25% phenol, to a final concentration of 
4x10® organisms of each strain per cc. Vaccines used in 
this study were lot 4446G (Ogawa) and lot 4445G (Inaba). 
The vaccines were diluted the night prior to vaccination, 
were promptly refrigerated, and remained refrigerated 
until the time of vaccine administration.
The dT and DPT vaccines were commercially manufactured 
vaccines (Wyeth).
B. Vaccine Administration
'The vaccine was administered to the deltoid region of the 
upper left arm, using the Ped-O-Jet (Scientific Equipment 
Manufacturing Company, Lodi, New Jersey). Intradermal 
vaccine administration was accomplished using the intra­
dermal (smallpox) nozzle. The subcutaneous vaccine was 
administered using the subcutaneous (measles) nozzle.
50seasohn, R.O., et al, (1965) Lancet, 1:450.
6Benenson, A.S., et al, (1968b) Bull. Wld. Hlth. Org. 38:359.
7Mosley, W.H., et al, (1969) Bull. Wld. Hlth. Org. 40:177.
8Mosley, W.H., et al, (1970) J. Inf. Dis. 121:S1.
^Mosley, W.H., et al, Op.Cit., 1969.
C. Subjects
The subjects for the study came from Ouagadougou Sector, 
Upper Volta, who were residents at the Petit Seminaire, 
Pabre, and the College Protestant, Loumbila. All were 
from 14 to 20 years of age. All of the participants were 
accepted in the order they appeared for the study and 
then assigned to an appropriate vaccination section based 
on previously selected random numbers.
D. Vaccination Schedule
All vaccinations were given during weeks 0 and 4 of the 
study, as indicated in Table I.
E. The Collection of Specimens
Finger tip blood specimens were collected during week 0 
just prior to the first cholera vaccination. Subsequent 
specimens were or will be obtained during weeks 2, 6, 10, 
and 16. In all instances, paired specimens were obtained 
prior to and following the appropriate vaccinations.
The finger tip blood specimens were collected in 0.05 ml 
capillary tubes (Microcaps, Drummond Scientific Company, 
Bromall, Pa.), and they were immediately placed into 0.45 
ml of sterile saline in a screw capped vial. These vials 
were placed in a field cold box and were transported to 
Ouagadougou at the end of each morning where they were 
placed in a refrigerator, centrifuged, and separated within 
24 hours. Separation was achieved through use of a standard 
laboratory centrifuge. The serum which was considered to be 
in a 1:10 dilution for analysis of titers was then frozen at 
-20°C, and was transported frozen to CDC for vibriocidal 
titer determination. Vibriocidal titers were measured at 
CDC using the micro technique of Beneson, et al.10
III. RESULTS
A portion of the results of the study to date are shown in Tables 
2 and 3 and in Figure 2. We arbitrarily defined seroconversion 
to be a four-fold or greater rise in antibody titer following 
the administration of cholera vaccine. The intradermal section 
has a percent seroconversion of 97.6 at two weeks. All of the 
people in the subcutaneous section showed seroconversion. No 
person in the control group demonstrated a significant change in 
antibody titer during the same period.
1°Benenson, A. S., et al, (1968a) Bull. Wld. Hlth. Org., 38:277.
The magnitude of the post vaccination vibriocidal titers are 
shown in Table 3 and Figure 2. The reciprocal geometric mean 
titer for the intradermal section at two weeks was 951. The 
value for the subcutaneous section was 2609. At six weeks the 
respective values were 384 and 1305. The control section had 
titers of 34 and 37.5.
DISCUSSION
The very high rate of seroconversion and the high level of the 
GMT found in this study population are comparable to that achieved 
at CDC in 1968 when EIS officers were vaccinated subcutaneously 
with the same vaccine. Thus, Africans with a generally lower 
standard of health and greater possibility of inter-current 
diseases appear to respond similarly to young American adults.11
Comparison of the geometric mean titers between sections provides 
an indication of the relative protective effect of the two methods 
of vaccine administration. Dr. Mosley has pointed out that we can 
expect approximately 50% decrease in the case rate for a given 
population for every doubling of the vibriocidal titer. Based on 
this information, we can predict a 95 and 98% protection during 
week 2 for sections B and D respectively. During week 6 the 
protection would be 89 and 97%. Although these predicted rates 
of protection are higher than those generally reported, we should 
remember that these are for only the first six weeks following 
vaccination. The measured protection of 46-80% reported from 
Pakistan cover periods up to 3-6 months following vaccination. 
Therefore, we can expect our GMT's to decrease with time, and the 
overall protection afforded by the vaccine to be lower than 
indicated presently.
Verway12 has shown that the decay of the plots of GMT against 
time are similar for a 200-fold range of cholera vaccine antigen 
potency and for different subcutaneous vaccination schedules.
We might therefore be able to assume that there will continue to 
be an approximate three-fold difference between the GMT's of 
sections B and D. While the differences in predicted protection 
at two and six weeks are not significantly different, the extrap­
olated protection at 10 weeks would be 76 and 94% for sections B 
and D. Thus, we may see a greater protection resulting from the 
subcutaneous vaccination after 2 1/2 months. However, this is 
speculation, and we will have to wait for the data.
^Gangarosa, E. J., Unpublished Data.
i2Verway, W. F., et al, (1969) Texas Reports on Biology and 
Medicine 27:Supplement 1, 243.
In summary, we can say at present, that the intradermal 
administration of cholera vaccine gives a predicted protection 
similar to that of the subcutaneous vaccine for a period of at 
least six weeks. The actual protection, however, can only be 
measured by the appropriate clinical trial in an area experiencing 
cholera disease.
A. Marshall McBean, M.D.* Medical Epidemiologist, Research and 
. Development, Smallpox Eradication Program, CDC
Andrew N. Agle, B.A. , Operations Officer, Smallpox Eradication 
Program, CDC
• > • . ■ J J * fc -,
Dr. Pierre Campaore, Directeur, Santé Rural, Upper Volta
Choiera Vaccine Study 
Upper Volta
Vaccination and Serum Collection Schedule
TABLE 1
Section B D E
Week 0 Blood Blood Blood
CV 0.2cc I.D. CV l.OOcc S.C. dT 0.5cc S.C.
" 2 Blood Blood Blood
" 4 dT 0.5cc S.C. dT 0.5cc S.C. dT 0.5cc S.C.
" 6 Blood Blood Blood
" 10 Blood Blood Blood
" 16 Blood Blood Blood
TABLE 2
Cholera Vaccine Study 
Upper Volta
Percent Seroconversion (>_ 4 Fold Rise In Vibriocidal 
Antibody Titer) Two Weeks Following Cholera Vaccination
Section B D E
Vaccine, Dose & Route CV 0.2cc I.D. CV l.Occ S.C. dT 0.5cc S.C.
Number of Subjects 42 37 22
Percent Seroconversion 97.6 100 0
Ogawa
Percent Seroconversion 90.4 97.3 0
Inaba
Sections B and D not significantly different at 0.05 level
TABLE 3
Cholera Vaccine Study 
Upper Volta
Reciprocal Geometric Mean Titers 
Against Ogawa Serotype
Section B D E
Week 0 24.0 22.3 28.3
" 2 951.0 2609 34.0
" 6 383.7 1305 37.5
TABLE 4
Cholera Vaccine Study 
Upper Volta
Estimated Percent Reduction in Case Rate 
Following Intradermal and Subcutaneous Cholera Vaccination
Section B D E
Week 2 95 98 0
" 6 89 97 0
» io* 76 94 0
*Extrapolated
Figure 2
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